

Antineutrophil cytoplasmic antibody-associated vasculitis in diffuse large B cell lymphoma

Vasculitis asociada al anticuerpo citoplasma antineutrófilo en el linfoma difuso de células grandes B

Dear Editor:

A 70-year-old Japanese woman with a 57-year history of hepatitis C virus presented with nausea, abdominal pain, and renal dysfunction. Physical examination revealed splenomegaly. Blood examination revealed elevated levels of C reactive protein (2.7 mg/dL), serum creatinine (2.46 mg/dL), blood urea nitrogen (22 mg/dL), and uric acid (7.8 mg/dL). Test for myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) was positive (71.2 U/mL). Urinalysis showed proteinuria (0.56 g/gCr) and microhematuria (>100 red blood cells/high-power field). ^{18}F -fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET-CT) revealed FDG accumulation in the cervical, thoracic, and abdominal lymph nodes and spleen (Fig. 1A). Abdominal computed tomography revealed splenomegaly with a low-density area (Fig. 1B). Renal biopsy specimen showed crescentic glomerulonephritis (Fig. 1C). Abdominal paraaortic lymph node biopsy revealed diffuse large B cell lymphoma

(DLBCL). Based on these findings, the patient was diagnosed with ANCA-associated vasculitis (AAV) and DLBCL with suspected splenic DLBCL. Treatment with R-CHOP regimen was initiated, and her renal function improved. However, no remission was noted for the DLBCL. The patient died 4 months later.

Although malignant lymphomas are occasionally complicated by autoimmune diseases,¹ complication with AAV is notably rare.² There have been recent reports of ANCA-positive cases with B-cell lymphomas, especially intravascular lymphoma.^{3–6} These cases, have included proven^{3,4} or unproven^{5–7} AAV. Moreover, an ANCA-positive case with splenic malignant lymphoma without proven AAV, as in this case, has been reported.⁷ Like the above cases with intravascular lymphoma and/or embolic damage,⁵ vascular damage caused by B cell lymphomas appeared to predispose the patient to ANCA. There have been reports of successful R-CHOP therapy, including rituximab, for both lymphoma and AAV.^{3–5} Recently, the RAVE⁸ and RITUXVAS⁹ trials




Fig. 1 – Findings of ^{18}F -fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET-CT), abdominal enhanced CT, and renal biopsy. (A) FDG-PET-CT shows FDG accumulation in the cervical, thoracic, and abdominal lymph nodes (yellow arrows) and spleen, indicating widespread lymphadenopathy and splenomegaly. (B) Abdominal enhanced CT shows splenomegaly (red arrow) with a low-density area. (C) Renal biopsy specimen reveals crescentic glomerulonephritis with fibrocellular crescent (arrow, Periodic acid-Schiff stain).

demonstrated that rituximab is effective for AAV, especially renal AAV. This is the first case of DLBCL-related AAV with biopsy-proven crescentic glomerulonephritis, and although R-CHOP did not provide lymphoma remission, renal function improved. Thus, rituximab could be effective for improving renal function in AAV. Clinicians should consider the possibility of AAV occurring as a complication in DLBCL.

Informed consent was obtained from the patient for the publication of this article.

REFERENCES

1. Bilici A, Yapici HS, Ercan S, Seker M, Ustaalioglu BB, Salman T, et al. The prevalence and significance of autoantibodies in patients with non-Hodgkin's lymphoma: are they correlated with clinicopathological features? *J Buon*. 2012;17:502-7.
2. Hamidou MA, El Kouri D, Audrain M, Grolleau JY. Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. *Ann Rheum Dis*. 2001;60:293-5, <http://dx.doi.org/10.1136/ard.60.3.293>.
3. Tsuda M, Nakashima Y, Ikeda M, Shimada S, Nomura M, Matsushima T, et al. Intravascular large b-cell lymphoma complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis that was successfully treated with rituximab-containing chemotherapy. *J Clin Exp Hematop*. 2015;55:39-43.
4. Shinkawa Y, Hatachi S, Yagita M. Intravascular large B-cell lymphoma with a high titer of proteinase-3-anti-neutrophil cytoplasmic antibody mimicking granulomatosis with polyangiitis. *Mod Rheumatol*. 2019;29:195-7, <http://dx.doi.org/10.1080/14397595.2016.1205798>.
5. Sugiyama A, Kobayashi M, Daizo A, Suzuki M, Kawashima H, Kagami SI, et al. Diffuse cerebral vasoconstriction in a intravascular lymphoma patient with a high serum MPO-ANCA level. *Intern Med*. 2017;56:1715-8, <http://dx.doi.org/10.2169/internalmedicine.56.8051>.
6. Muto G, Takahashi Y, Yamashita H, Mimori A. A patient with intravascular lymphoma presenting with cerebral infarction and a high serum MPO-ANCA level. *Mod Rheumatol*. 2011;21:207-10, <http://dx.doi.org/10.1007/s10165-010-0361-z>.
7. Zuckerman KK, Leventhal L, Wynne C. Positive c-ANCA in a patient with lymphoma and without vasculitis. *J Clin Rheumatol*. 1997;3:279-81, <http://dx.doi.org/10.1097/00124743-199710000-00007>.
8. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*. 2010;363:221-32, <http://dx.doi.org/10.1056/NEJMoa0909905>.
9. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med*. 2010;363:211-20, <http://dx.doi.org/10.1056/NEJMoa0909169>.

Taro Horino^{a,*}, Osamu Ichii^b

^a Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi 783-8505, Japan

^b Laboratory of Anatomy, Department of Basic Veterinary Sciences, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-Ku, Sapporo 060-0818, Japan

* Corresponding author.

E-mail address: horinott@yahoo.co.jp (T. Horino).

<https://doi.org/10.1016/j.nefro.2020.04.017>

0211-6995/© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Predictor factors of inappropriate rivaroxaban dosage using the Ckd-Epi equation[☆]

Factores de predicción de dosificación inadecuada de rivaroxabán utilizando la ecuación de CKD-EPI

Dear Editor,

Rivaroxaban is approved for preventing stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors. It is recommended that the Cockcroft-Gault (CG) equation be used for the dosing

of this drug.¹ However, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is the method of choice for determining kidney function and is the equation used by the majority of laboratories in Spain.² There are discrepancies in values calculated using the two equations which may cause errors in prescribed doses of rivaroxaban.^{3,4} Prescription of inappropriate doses is linked to an adverse cardiovascular

DOI of original article:
<https://doi.org/10.1016/j.nefro.2020.04.016>.

[☆] Please cite this article as: Pérez Cabeza AI, Górriz JL, Bravo Marqués R, Chinchurreta Capote PA, López Tejero S, González Correa JA, et al. Factores de predicción de dosificación inadecuada de rivaroxabán utilizando la ecuación de CKD-EPI. *Nefrología*. 2021;41:216-218.